Current and emerging antiviral treatments for hepatitis C infection
Joseph S Doyle, Esther Aspinall, Danny Liew, Alexander J Thompson, Margaret E Hellard
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | WILEY | Published : 2013
All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work, JD and EA had no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years, MH received research support from Roche, DL received honoraria from Abbott and Merck, and AT received research/grant support from Merck, Roche Pharmaceuticals, Gilead Sciences and speaker's fees from Merck, Roche Pharmaceuticals, Bristol-Myers Squibb, JD, EA, DL and MH had no other relationships or activities that could appear to have influenced the submitted work, and AT had a consulting/advisory capacity with Merck, Roche Pharmaceuticals, Janssen-Cilag (Johnson and Johnson) and is a co-inventor of a patent related to the IL28B-HCV discovery.JD, AT and MH acknowledge fellowship support from the National Health and Medical Research Council. JD and MH acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Programme (Department of Health, Victoria, Australia) to the Burnet Institute.